PHARMACY

AmerisourceBergen adds resources to support independent pharmacies

BY Gina Acosta

LAS VEGAS – AmerisourceBergen is launching several new programs to help independent pharmacies improve business performance while meeting growing patient need.

“At AmerisourceBergen, we are championing the independent pharmacist,” said president of Good Neighbor Pharmacy, Brian Nightengale, RPh, Ph.D. “Whether it is hearing feedback from our customers about how to improve their buying experience or delivering new solutions to enhance business profitability and patient care, we are fully committed to supporting the success of independently owned community pharmacies.”

The company highlighted the new solutions at ThoughtSpot 2016, Good Neighbor Pharmacy’s annual trade show, in Las Vegas. AmerisourceBergen leaders highlighted solutions designed to drive improved results across the entire pharmacy – from front-end sales to back-end operational performance.

Resources include:

Advocacy Resources: As part of AmerisourceBergen’s ongoing support for independents, the company has added a new resource, OurIndependentVoice.com. The newly launched website provides pharmacists a centralized place to access tools and resources to join advocacy movements that impact care in the community setting, research policies impacting independent pharmacy, access letter templates and write to legislators, and connect with other pharmacists and pharmacy organizations.
Specialty at Retail: The rapid growth of specialty products provides a natural intersection for community pharmacy to provide personalized patient care in complex therapies. These specialty products often have a high burden of administrative tasks that can be challenging for an independent pharmacy to operationalize economically. AmerisourceBergen is developing a specialty at retail program that will allow member pharmacies to better service patient needs while diversifying revenue streams. Through this program, independent pharmacies will be able to focus more on patient care instead of spending time and resources navigating administrative tasks.
Front-End Retail Excellence: Good Neighbor Pharmacy is offering its members comprehensive services to optimize front-end sales, including access to business coaching, manufacturer promotions, point of sale (POS) data and reporting tools, and Retail Remedy, a monthly publication with news, tips, and product specials focused on retail strategies. While at ThoughtSpot 2016, many pharmacists joined an all-day front-end profit building seminar presented by the National Community Pharmacists Association (NCPA) and sponsored by Good Neighbor Pharmacy. This session kicked off a new five-year partnership to provide similar learning opportunities in convenient settings for pharmacists.
Generics Buying Enhancements: AmerisourceBergen has redesigned the generics buying experience to not only deliver competitive up-front prices, but to serve pharmacists differently based on the way that they want to buy.

New to ThoughtSpot this year was an Innovation & Technology Showcase. Throughout the conference, attendees could visit the showcase to learn more about:

• ABC Order, a new ordering platform developed with pharmacists for pharmacists. The platform is engineered to fit within the pharmacy workflow to enable effortless ordering, smarter inventory control, quicker access to data and simple issues resolution. The new platform will be made available to customers in 2017
• Best practices for medication therapy management (MTM) programs to manage adherence and patient communications, and working with Medicare
• How partners of AmerisourceBergen’s Pharmacy Services Administrative Organization (PSAO), Elevate Provider Network, implement technology solutions to support reimbursement discussions with payers, and improve MTM, adherence and reimbursement

Good Neighbor Pharmacy’s 2016 Pharmacy of the Year Award was announced during general session. HB Pharmacy from North Arlington, N.J. received the esteemed award for exemplifying what it means to be a Good Neighbor Pharmacy in their commitment to enhancing patient care and lives in local communities. Since Gaspar Bellitti opened HB Drugs in 1964, the family-owned pharmacy has remained committed to its innovative, patient-minded approach to care. Driven in part by his father’s ideals, owner John Bellitti has invested in technology solutions that enable the staff to spend more time with patients. Under his leadership, the pharmacy has adopted an integrated approach to patient care, operating with the core belief that a person’s health and wellness requires a collaborative effort among all healthcare practitioners.

Following the Pharmacy of the Year announcement, retired NASA astronauts and twin brothers Scott and Mark Kelly delivered the keynote address. The astronauts reflected on the experiences and lessons that shaped their perception of teamwork and leadership, discussed how they learned to face and overcome adversities and shared personal strategies for adapting to change.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Teva gets FTC approval for Allergan generics acquisition

BY David Salazar
JERUSALEM — The Federal Trade Commission has approved Teva’s proposed consent order for its planned acquisition of Allergan’s generics business, Actavis Generics, the company announced Tuesday. With the final regulatory hurdle behind it, the company said it expects the $40.5 billion transaction to complete next week.  
 
“We are pleased to have received all of the requisite regulatory approvals for our acquisition of Actavis Generics,” Teva president and CEO Erez Vigodman said. “This acquisition is a transformative step for Teva as we continue to claim a differentiated space in the global pharmaceutical industry. The generics industry is one of the most attractive industries in the world in terms of growth rates, profitability, return to investors and contribution to healthcare systems and societies around the world.”
 
Teva expects the acquisition to bring in $1.4 billion in operational and tax synergies by the end of 2019, with a 14% accretion in earnings per share in 2017 and 19% in 2019. From the time the deal closes to the end of 2019, Teva said it expects to generate more than $25 billion of free cash flow that it says will allow it to pursue other acquisitions to expand its presence in key growth markets. 
 
“The new Teva will be ideally positioned to realize the opportunities the global and U.S. generic markets offer,” Vigodman said. “The transaction strongly reinforces our strategy and yields very compelling economics. As a result, it opens a new set of possibilities for us in generics and specialty medicines.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Adlyxin to treat type 2 diabetes

BY Gina Acosta

WASHINGTON — The U.S. Food and Drug Administration has approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

"The FDA continues to support the development of new drug therapies for diabetes management,” said Mary Thanh Hai Parks, M.D., deputy director, Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “Adlyxin will add to the available treatment options to control blood sugar levels for those with type 2.”

Type 2 diabetes affects more than 29 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness and nerve and kidney damage.

Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. The drug’s safety and effectiveness were evaluated in 10 clinical trials that enrolled 5,400 patients with type 2 diabetes. In these trials, Adlyxin was evaluated both as a standalone therapy and in combination with other FDA-approved diabetic medications, including metformin, sulfonylureas, pioglitazone and basal insulin. Use of Adlyxin improved hemoglobin A1c levels (a measure of blood sugar levels) in these trials.

In addition, more than 6,000 patients with type 2 diabetes at risk for atherosclerotic cardiovascular disease were treated with either Adlyxin or a placebo in a cardiovascular outcomes trial. Use of Adlyxin did not increase the risk of cardiovascular adverse events in these patients.

Adlyxin should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).

The most common side effects associated with Adlyxin are nausea, vomiting, headache, diarrhea and dizziness. Hypoglycemia in patients treated with both Adlyxin and other antidiabetic drugs such as sulfonylurea and/or basal insulin is another common side effect. In addition, severe hypersensitivity reactions, including anaphylaxis, were reported in clinical trials of Adlyxin.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?